TSPO and myeloid sarcoma: Recent research has demonstrated significant promise with TSPO agents in progressive MS clinically isolated syndrome in the cortex of MS patients that correlates with disease severity, suggesting TSPO agents have the potential to correlate better with disease severity compared to conventional MRI, making visible hidden disease and assisting in patient individual response analysis to therapy [23,24,25].